We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Preleukemic Hematopoietic Stem Cells Identified in Acute Leukemia

By LabMedica International staff writers
Posted on 12 Mar 2014
A preleukemic stem cell has been discovered that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).

AML is an aggressive blood cancer that starts in stem cells in the bone marrow. More...
A mutation in a gene causes preleukemic stem cells to develop that function like normal blood stem cells but grow abnormally. These cells survive chemotherapy and can be found in the bone marrow at remission, forming a reservoir of cells that may eventually acquire additional mutations, leading to relapse.

Scientists at the Princess Margaret Cancer Center (Toronto, ON, Canada) and their international collaborators carried out genomic analysis of more than 100 leukemia genes on many patient samples. Genomic DNA was subjected to limited whole-genome amplification (RepliG, Qiagen; Valencia, CA, USA) to obtain the required amount of input DNA for the SureSelect protocol (Agilent; Santa Clara, CA, USA).

Amplified genomic DNA was mechanically sheared using the M220 Focused-ultrasonicaton (Covaris; Woburn, MA, USA) and sequencing adaptors (Illumina; San Diego, CA, USA) were ligated to fragments to make a sequencing library. Droplet digital polymerase chain reaction (ddPCR) on genomic DNA and fluorescence-activated cell sorting of human stem/progenitor and mature cell populations were also carried out.

The investigators discovered that that in about 25% of AML patients, a mutation in the gene DNA (Cytosine-5-)-Methyltransferase 3 Alpha (DNMT3a) causes preleukemic stem cells to develop that function like normal blood stem cells but grow abnormally.

John Dick PhD, a professor and the senior author of the study said, “Now we have a potential tool for earlier diagnosis that may allow early intervention before the development of full AML. We can also monitor remission and initiate therapy to target the preleukemic stem cell to prevent relapse. Our study suggests that in some cases the chemotherapy does, in fact, eradicate AML; what it does not touch are the preleukemic stem cells that can trigger another round of AML development and ultimately disease relapse.”

The study was published on February 12, 2014, in the journal Nature.

Related Links:

Princess Margaret Cancer Center
Qiagen 
Covaris




Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Automated Coagulation Analyzer
Hemolumi H6
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The two new tests are used with the LightCycler 480 and LightCycler PRO instruments (Photo courtesy of Roche)

New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance

Cyclospora cayetanensis, a food- and waterborne intestinal parasite, can cause prolonged diarrhea, fatigue, and abdominal cramping, placing added strain on urgent care and emergency departments during outbreaks.... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.